CBD Oil for Kids – Everything you Need to Know
When it comes to your children’s wellbeing, there is nothing you wouldn’t do. Their health is important to you, and if your child is suffering, you would want to help them in any safe way that you can.
Although modern medicine has come very far, there are still some areas where children are struggling. Epilepsy, anxiety, ADHD, and cancer are prevalent among kids and require strong medications to treat. Some people do not think these medicines are suitable for children.
Perhaps you have seen the latest developments in CBD for kids and have started considering this natural remedy. Naturally, you’ll have plenty of questions about its safety and effectiveness. Once you’ve learned more about this, you can start looking at CBD for anxiety, ADHD, and other conditions.
Is CBD Safe for Kids?
Cannabidiol (CBD) is one of the two most well-known cannabinoids – the other being tetrahydrocannabinol (THC). THC is psychoactive and is not recommended for children. CBD, on the other hand, is not a psychoactive compound and offers a wide range of benefits.
Does that mean it is okay for your children? Although cannabis is still a relatively new field of research, there are plenty of studies being conducted about the benefits of CBD for children and adults.
There is still a big divide in the medical (and parenting) industry about whether or not children should be using CBD or other cannabinoids for medicinal purposes. Regardless of what you believe, you don’t have to ask ‘can a child overdose on CBD oil?’ because the answer is – No!
Top 5 Therapeutic Benefits Of CBD
Now that you know CBD is safe, it’s time to look at the specific positives. There’s no point introducing a new substance into your child’s life if it isn’t going to do anything. Here is a list of the top medicinal uses of CBD cannabis oil.
1. CBD for Anxiety
Although it might not seem like it, Anxiety is a serious problem our children are facing. According to a recent study, as many as 7% of children between the ages of 3 and 17 suffer from anxiety. Not only can anxiety itself be difficult to deal with, but it can lead to other problems in your child – like depression, sleep disorders, or even ADHD.
CBD and anxiety prevention go hand in hand. Not only can it help you after a long day of work, but CBD for kids with anxiety works really well. A recent study has found CBD to be a useful alternative to conventional anti-anxiety and anti-depression medication.
These medications are generally quite a lot for children to handle, so it is great news to know that there is a natural remedy that might work just as well.
Image by Wokandapix on Pixabay.
2. CBD for ADHD
Nowadays every parent knows about ADHD. This attention disorder is becoming increasingly common.
ADHD is a condition that affects an estimated 1 in 20 children in South Africa. The choice recommended by most doctors is either Ritalin or Concerta, but these have many negative side effects that parents and children aren’t comfortable with.
If you would prefer to try a natural route, there is plenty of anecdotal evidence to support the use of CBD oil for kids with ADHD. Unfortunately, there are no clinical studies that prove the benefit of CBD for ADHD yet, but there are many people and parents who can vouch for the benefits.
Many people have found that, with the help of CBD they were able to reduce or even stop their ADHD medication entirely. For parents who are concerned about the long term effects of these medications, it is worthwhile to start talking to your doctor about it.
3. CBD for Epilepsy
Epilepsy is the most uncommon condition on the list, but it is one that can make life extremely difficult for children and their families. The daily, sometimes hourly, seizures are enough to make any parent want to find a solution.
Although there are epilepsy medications available, they are very strong and can cause mental and physical side-effects. Luckily, CBD is one of the best natural remedies for epilepsy currently available.
A great thing about this remedy is that it has been thoroughly researched. You can find plenty of studies, like this one, that shows how CBD benefits both children and adults suffering from seizures.
If you prefer reading about people’s lives, you can look at two-year-old Jaelah Jerger. This little girl had terrible epilepsy, with up to 30 seizures a day. Her parents first tried conventional medicine, but after it failed, they switched to CBD. The success they had was unbelievable and since then many parents have been reporting similar stories.
4. CBD for Pain & Inflammation
One of the most commonly used benefits of CBD is for pain relief. You have cannabinoid receptors throughout your body that can help with reducing pain and inflammation. If your child is suffering from either of these – even if it’s just a sprained ankle – a mild dosage of CBD could help.
You will not need to use large dosages to help with pain. The products mentioned in the next section can all be used for pain relief, but you should monitor the dosages.
5. CBD for Sleeping Disorders
Does your child struggle to sleep at night? Whether they can’t fall asleep easily or they are having bad dreams, CBD can be a useful substance. It is not a soporific – which means it won’t make you fall asleep like a sleeping pill – but the other benefits, like relaxing the body, all aid in getting a good night’s rest.
Some of the leading causes of sleeping disorders are anxiety, ADHD, and pain. All of these have been previously mentioned and can be treated using CBD. By reducing your child’s stress, hyperactivity, or pain, you should see significant improvements in their sleeping patterns. This will improve your child’s day-to-day life tremendously.
Image by Sammy-Williams on Pixabay.
Best CBD Oil for Kids
Now that you know CBD is safe and effective, you should consider which CBD oil kids can use. Since South Africa legalized CBD, the number of available products has gone through the roof. You will, however, want to find the best option for your child’s specific needs.
The most important thing is to buy a good quality product. As long as the CBD oil is 100% natural and does not contain any harmful ingredients, your children will be perfectly safe. All you need to do now is work out the correct CBD oil dosage for anxiety, ADHD, cancer, or any other condition your child might have.
If you are still a little concerned about the safety of the products, or you want to know what your child will feel when they take CBD, simply try it yourself first. You can use yourself as a guinea pig, and give yourself peace of mind. After all, experiencing something for yourself is the best way to develop confidence in a product.
By working with this guide and a medical practitioner, you will be able to accurately and safely work out exactly how much CBD is right for your child.
Image by HaiBaron on Pixabay.
CBD Oil for Kids with Anxiety
These products can help your child perform better at school, play with other children more, and help them get a good night’s rest. If your child is suffering from anxiety, you can consider these products because they allow for low, medium or high doses of CBD.
Dealing with anxiety is not a one-size-fits-all approach. You should be in communication with your child’s doctor to determine the perfect starting dose as well as how to increase the dosage if you find he needs more.
● Cannaco Gummies 60mg – by Taste of Cannabis
The first product on our list is perfect for any child. These tasty CBD gummies are made with both natural flavouring and colourants. Each packet contains 15 gummies with 4mg of CBD each (60mg total).
The great thing about this product is that you can start off with a very low dose of CBD by just giving your child one gummy. You can wait 10 – 15 minutes before deciding whether he should have another one or not. The maximum recommended dosage is 3 (12mg), but as per South African law, your child can take up to 5 (20mg) per day.
● Junior CBD 300mg – by AfricanPure
These isolate-based CBD oil drops are perfect for children. There are no harmful ingredients or THC present. CBD oils often don’t have the best taste, Junior CBD is different. This product now comes with natural strawberry flavouring, making it a remedy that your children will love.
Thanks to the dropper, this is a straightforward product to administer. Every ten drops contain 0.5ml (approximately 2mg of CBD). You can start low with 10 drops and slowly increase the dosage if you find it necessary.
● Everyday Gel Capsules 300mg – by AfricanPure
Everyday Gel capsules are an easy-to-swallow pill containing hemp-derived CBD. This product contains 30 capsules, with a total of 10mg CBD each. Because you can only start at 10mg, it is best to use this product If you already have experience with CBD for kids. We recommend starting with a product where you can administer between 2 – 5mg of CBD.
Once you know your child needs higher dosages, you can start taking 1 or even 2 tablets daily. Two tablets would equal 20mg of CBD, which is the legal recommended dosage in South Africa.
CBD Oil for Kids with ADHD
Choosing the correct CBD product for your child with ADHD can be challenging, so it is always best to do so with the help of your doctor. You will want to start low, but could find that higher doses are needed to limit your child’s dependance on his ADHD medication.
● Hemp Oil Liposomes 300mg – by Elixinol
Elixinol is a South African company that makes some of the highest quality CBD oils on the market. This product is one of their most popular. It comes in a small glass bottle with an easy-to-use spray pump dispenser.
Each bottle contains 300mg of CBD hemp oil, and there are approximately 60 servings (5mg per serving). A large reason why this is CBD kids enjoy is because of the natural flavour. There are four flavours available, namely orange, lime, cinnamint, or coconut.
Another great thing about this product is that it isn’t administered sublingually (under the tongue) – which some children don’t like. Instead, you put the CBD Liposome into water or your kid’s favourite juice.
CBD Oil for Kids with Seizures
CBD oil is one of the best natural ways of treating epilepsy. If you’d like to see if it can help your child, you should first consult your doctor and then try one of the following products.
● CBD Isolate Oil Drops – by Goodleaf
This product is made using CBD isolate, which is recommended for children because it contains no THC. 600mg of CBD is combined with MCT oil to fill a 30ml container. Children suffering from seizures would usually require higher dosages. You should work your way up to the South African legal recommended daily dose of 20mg CBD.
● Adco CBD Daily 10 – by CBD Store
The last item on our list is the tastiest. These CBD gummies for kids are the perfect snack, which will get them excited for their daily intake. There are 30 pastilles per container, each containing 10mg of CBD. These sweets contain sugar and are available in 30 assorted flavours. If you need to go up to the maximum legal dose per day, you simply need to eat 2 of these sweets – an easy feat for any child.
Final Thoughts on CBD and Kids
Although plenty of research needs to be done, things are looking good for CBD oil and kids. There is plenty of evidence to suggest that it can be used to treat anxiety, seizures, and ADHD – three things affecting children worldwide.
Even if you are ready to go out and buy CBD, It’s still important to consult a doctor first. We wish you luck and hope that the CBD provides your children with the relief they deserve!
Cbd Oil Uk State Times
Cbd oil uk Hemp Cream Near Me can you use cbd oil with tramadol Cbd Ointment Pure cannabis oil stayed the same color Approved by FDA how to melt thc oil thats in a cartridge is 4mg hemp cbd oil safe for a child cbd oil uk Cbd Oil For Sale Near Me State Times. After thinking about this cbdmedic arthritis cream Wu Zhu, he probably said it was Chonghua, it was Qin Mu He had this heart, but he didnt have this strength The souls with so many sexual excesses, even the infants with the easiest excesses. Didnt you hear your own roar just now? Gulian glanced at him and said slowly But now the whole room seemed to have a cbd massage oil for sale big ruthless hand strangling everyones throats and no cbd oil uk sound was heard The girl yelled in the room like she collapsed She also seemed to find that she couldnt make a sound. and you dont need the 500 000 achievements My Yanlong Legion will reward you with 500,000 achievements, which will take effect immediately. Although this giant, even a ghost and god, had just been formed, Wu Yu guessed that this giant must have been a horror before What I felt in my body was a kind of lofty standing on the top of all beings. Wu Yu stopped and listened to them Of course, secretly, the other party couldnt find Wu Yu now I dont cbd oil uk know what those powerhouses are doing. A living soul is a soul that has just died less than a cbd oil uk year ago, and Qin Mus soul at this time Although he was out of the body, his soul was incomplete because his body was not dead If Qin Mus soul had been explained here, then the fifteenth generation of Wuzhu would have disappeared silently. Shao Chenglong was a little embarrassed, We only have a few motorcycles in our village Your village is too poor! Where did the mountain leek money go? Bei Le Shui looked how to melt thc oil thats in a cartridge incredible The mountain leek has only been a few days now Shao Chenglong said. Yes! President Shi also reacted, How can we have so many mountain leeks? Why do you think I want three hundred catties of mountain leeks? Zong Yongchun said Isnt it distributed to other restaurants When Mr Shi asked, he felt stupid Of course not It was sent to the capital for cbd oil uk a mountain leek feast. In the past, I didnt know the existence of souls, but under the stimulation of this supernatural 750 mg cbd oil with thc power, Wu Yu had the outline of souls At least he knew where the pain was After the supernatural powers rushed past there were places where the pain occurred Are the places where the souls exist Tingling, ferocious. Zhao Laoshi also came to help, and the three of them were in a hurry Putting Tong Cheng down, the discerning person of cbd oil uk Tong Cheng at this time was wrong. many people from the Beiming clan were unhappy again Originally, Wu Yu had received cbd oil uk enough rewards Now, with 500,000 merits, he must change a lot of things again Wu Yu now Taking anything away is equivalent to transferring things from the Beiming Empire to the ancient Yanhuang Kingdom. Therefore, he cbd oil uk must use violent storm attacks before the opponent, and burst out one after another, without giving the opponent a chance to breathe! However, the opponent is also aware of this. There are other stick bones, chicken, eggs, pork belly, bacon, all of which are produced by Shitou Village, according to the cost price Its less than five hundred, according to the market price, which thc oil vape atomizer means that the total cost is more than three thousand. Then Zhao Laoshi not only gets cheap but cbd oil uk Popular cbd face products also sell good, he even bent over and retched, that soul Jingyi After entering the new orleans cbd for sale mouth, it turned into water, and it was long gone. Thats the right thing, Xiao Ming, A Fang, you accompany Xiao Shao to pick it, he picks it up, and you go through the transfer procedures for him Tang Hao said, Im tired and need a rest By hemp joint cream the way. cannactiva rx cbd oil the power of tens of thousands of clones is still quite terrifying The opponent has the tenth level of the Yuanshen realm, so he successfully blocked Wu Yus attack, but was also hit by this force.
1. cbd oil uk lakeside medical center cbd oil study cleveland ohio
At that time, Bei Le Thats what the water said, but Tang cbd oil uk Zhengming dismissed it and gave Number 1 cbd ointment a big reason cbd oil uk if it is not bought at a low price, and sold at a high price. The most important thing is the law! Director Zhang said, If the legal facts are wrong, then the attitude cbd oil uk is irrelevant Especially young people like you. Xiaobai couldnt complain, so he couldnt order yellow cbd oil uk and white things The family was too poor to open the pot, and he ate instant noodles all day long. Xiao Bai installed the Talishui, bounced downstairs, heard the voices of several people in can vaping cbd oil cause high blood pressure the hall, and asked curiously Mu Mu, can I go? Qin Mu suddenly felt his head Its all big Yu Xiu glared at him The latter spread his hands and expressed helplessness Qin Mu lightly coughed Miss Sikong Call me Lulu! Sikonglu stomped her feet shyly. Boss Li said, We are also burdened by the poor economy In cbd oil uk the past few years, I didnt make much money, but I dont have to worry about selling hard work This year is really not good, there is no project at all. After Wu Yu noticed it he cbd oil uk immediately reminded them that before that, because he had been out for Topical are there specific vape pens for cbd juice a period of time, he inhaled the smell less Now he noticed that he still felt dizzy. He took his sister to the elementary school, junior high school and high school He told her that he hadnt read a book systematically, but only recognized a few words. Zong Yongchun cbd oil uk had no choice but to get things out of the way What? Tang Xiaoshan couldnt sit still cbd oil uk immediately, How could he be caught by the police? Im not so sure either. The third uncle walked to the front of the car and coughed Just as he was about to say something, Shao Chenglong opened the door and came down Three uncles. Its on fire! on fire! Get up! How could it catch fire! Many people gushed out of the tent and found Supplements cbd oil for pain for sale that the warehouse tent was on fire Several blankets cbd and hemp oil products soaked in water were pressed on, and the fire was immediately extinguished. The Supreme cbd oil uk Master of the Criminal Department next to him understood him very well, because his son Gong Shenjun had just been bullied by Wu Yu not long ago Both of them were great figures in the Northern Ming Empire. He can only rely on the formation The law can be completed, and the most important thing for cbd oil uk launching such a formation is time cbd oil uk now. Yes Azi said, Brother Along collects twenty Cbd Ointment yuan, but he is worried that other people will hide the mountain leek secretly and sell it Then Brother Along is at Branded can cbd oil help after cauda equina surgery a loss Along, dont worry! Azis father said, We only have one bus a day here I go to the bus stop to cbd oil uk guard it. Its because of poor eyesight for a while, wronged Wu Zhu The Taoist priest was rather thickskinned, and his words were light and light, cbd oil uk covering everything Yes how can there be no clumsy eyes in a persons life, but I dont understand thateternal benefit very well, I hope. Zong Yongchun has eaten countless kinds of dishes, what? There are eight major cuisines, domestic and cbd oil uk foreign, pigs, cows, chickens, ducks, and everything No matter what ingredients or methods, Zong Yongchun knows after a sip. Maybe the two have a good relationship, but the emperor, except for the ancient emperor of Yanhuang, only Uncle Yong Huang has the cbd oil uk power to grant the status of emperor The ancient emperor cbd oil uk of Yanhuang is normal.
2. what to do with leftover cannabis honey oil
Seeing this, Qin Mu almost cursed, can this old man lie down for a hemp oil for dogs walmart while, and wake up so soon? Maybe it was because Qin Mu and the old monk were fighting the Ziying too much, or Sikong Wenzheng let the baby kiss him, anyway. cbd oil uk Xiaobai made Sagong choke like this, a little uncomfortable If you want to I know, just look at it for yourself, who stopped you? Sikonglu glared at Xiaobai, and the two of them were about to quarrel when they saw it. but didnt notice that his body was getting weaker and weaker inexplicably, and his physical discomfort was habitually attributed to cbd oil uk the sequelae of deprivation No matter that much if you find something like that before this, it will be fine when the organization comes to rescue him. the more complex and the more powerful they are Wu Yu has not encountered the magic for the how to melt thc oil thats in a cartridge time CBD Tinctures: can i put thc oil in my vape being Fewer arrays are more powerful. Mu Mu, how cbd edibles portland do you know cbd oil uk which Zhu Tian has a life span of only 30 years? Xiao Bai was a little frightened, dear, as soon as Zhu Tians servant came out of the alley. and if youre on the sixth floor hey The terrain is not good, and it is full of rocks It is possible to cbd oil uk say that Fengwan Town will be demolished. But Shao Chenglong is determined to keep this from his parents in advance If they find out, Im afraid that Shao Chenglong will immediately sell the things and go to the city to buy a house with the cbd prescription california money. the mysterious cbd oil uk weapon would definitely not be told How do you know my dream Ye Xixis eyes widened and his face was incredible You say yes, I will give you the answer later Wu Yu said Oh, good. Wu Yu is now using the body of the swallowing body cbd oil uk to suppress the sword energy of the other party, and the other party depends on this. After cbd oil uk the past, perhaps because he was afraid that Qin Mu would chase after him, even if Qin Mu hit his back suddenly, he refused to stop and left the ward quickly Qin Mu hurriedly ran after him, holding the slippers tightly in his hand, and saw the other party. It is hemp seed same as cbd oil a gathering place for resentment, and Xiao Gao He has a psychic physique If Qin Mu doesnt make a move and allows the opponent to develop, Xiao Gao will be able to see Doctor Yu cbd oil uk in no time. Suddenly at this moment, a cbd oil uk reversal appeared! From within the giant cauldron, suddenly came out the thick, rough, explosive voice Emperor Yu, is it so patience! If you want to defeat me like this, then you are too naive. The floating tower was only slightly When you show up, no one should understand what it is In a blink of an eye, the cbd for sleep for sale black ball exploded and was divided into three batches. This is not an ordinary gambling battle of spirits, but an important turning point for Emperor Yan He has had enough of this kind of plain contention and Wu Yu is very cbd oil uk tired It stands out He also hopes that he can change and let others notice him Emperor Yans eyes have changed. If he cant get the concoction, the promotion of mountain leek nourishing the stomach will be half the effort What does Miss Tang mean? Zong Yongchun actually didnt understand cbd oil uk what Tang Xiaoshan was here for. Thats tens of thousands You can also use this highpaying job to buy off your subordinates for your own use The local snake absolutely likes it cbd oil uk Its not a question of how many people and how many days. Cbd oil uk Cbd Oil For Sale Near Me Online Marketplace cbd oil in defiance ohio Cbd Ointment Number 1 how to melt thc oil thats in a cartridge cannabis oil stayed the same color Hemp Cream Near Me how to use cannabis oil for acne State Times.
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known.
The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations and plant-derived cannabinoid isolates in mood, anxiety, sleep, psychotic disorders and attention deficit/hyperactivity disorder (ADHD) is discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational and public health elements, and future research recommendations. The systematic review of the literature was conducted during 2019, assessing the data from all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for all major psychiatric disorders (neurological conditions and pain were omitted).
The present evidence in the emerging field of cannabinoid therapeutics in psychiatry is nascent, and thereby it is currently premature to recommend cannabinoid-based interventions. Isolated positive studies have, however, revealed tentative support for cannabinoids (namely cannabidiol; CBD) for reducing social anxiety; with mixed (mainly positive) evidence for adjunctive use in schizophrenia. Case studies suggest that medicinal cannabis may be beneficial for improving sleep and post-traumatic stress disorder, however evidence is currently weak. Preliminary research findings indicate no benefit for depression from high delta-9 tetrahydrocannabinol (THC) therapeutics, or for CBD in mania. One isolated study indicates some potential efficacy for an oral cannabinoid/terpene combination in ADHD. Clinical prescriptive consideration involves caution in the use of high-THC formulations (avoidance in youth, and in people with anxiety or psychotic disorders), gradual titration, regular assessment, and caution in cardiovascular and respiratory disorders, pregnancy and breast-feeding.
There is currently encouraging, albeit embryonic, evidence for medicinal cannabis in the treatment of a range of psychiatric disorders. Supportive findings are emerging for some key isolates, however, clinicians need to be mindful of a range of prescriptive and occupational safety considerations, especially if initiating higher dose THC formulas.
The Cannabaceae family is a comparatively small family of flowering plants encompassing 11 genera and approximately 170 different species, a small number of which elicit a range of varying psychoactive effects . Several medical applications have been studied over the past decades, with the National Academies of Sciences, Engineering and Medicine (NASEM) recently holding the position that cannabis and cannabinoids demonstrate conclusive or substantial evidence for chronic pain in adults, chemotherapy-induced nausea and vomiting and spasticity in multiple sclerosis, with limited evidence for use in increasing appetite in HIV/AIDS patients and improving symptoms of post-traumatic stress disorder (PTSD) .
While there is increasing psychiatric interest (and debate) regarding the potential mental health applications (in concert with concerns over the potential for triggering latent psychosis), historical evidence for the use of cannabis in mental health conditions is remarkably ancient. For instance, the Shen-nung Pen-tsao Ching (Divine Husbandman’s Materia Medica) described its benefit as an anti-senility agent [3, 4], while in the Assyrian culture, cannabis was indicated as a drug for grief and sorrow [5, 6]. Sections of the Indian Atharva Veda (1500 BCE) suggest bhanga (Cannabis) exerted anxiolytic effects [5, 7], while in 1563, Da Orta  described cannabis as allaying anxiety and engendering laughter. With respect to modern use, contemporary consumers of cannabis report (as assessed via meta-analysis of patient usage data) that pain (64%), anxiety (50%), and depression/mood (34%) are the most common reasons .
Increasing scientific research, conducted over recent years, has seen the regulatory pendulum swinging away from the United Nations Single Convention on Narcotic Drugs in 1961 (which recommends enforcement of cannabis use as illegal) , towards consideration of its potential use in medical conditions. Recent scientific evidence ascribes anxiolytic, neuroprotective, antioxidant, anti-inflammatory, antidepressant, anti-psychotic and hypnotic pharmacological actions due to several phytochemicals commonly found in the cannabis genus [11, 12].
While Δ 9 -tetrahydrocannabinol (THC) is considered the main psychoactive constituent, other cannabinoids have also revealed less potent psychotropic effects. These include cannabidiol (CBD) , Δ 8 -tetrahydrocannabinol , and other less-studied cannabinoids including cannabinol (CBN) and Δ 8 tetrahydrocannabivarin (THCV) . Further, many other constituents such as the terpenes (i.e. volatile organic compounds found mainly as essential oils in many plants), also provoke a range of biological effects, and produce the characteristic aroma of the plant . The hundreds of cannabis chemovars or varieties (commonly referred to as strains) developed over millennia have unique and complex constituent profiles, of which each may provide targeted therapeutic usage due to the unique synergistic combination of plant chemicals. Some pharmaceutical preparations have attempted to isolate the key constituents (there are over 140 phytocannabinoids ) to provide standardised formulas that may harness this ‘entourage effect’ [16, 18], while being able to provide batch-to-batch assurance of the medicine.
While other reviews have covered cannabis’ use in a range of conditions (cf. Whiting et al. 2015  for a general review of evidence for medicinal cannabis), none to date have provided both a systematic and ‘clinically-focused’ review on psychiatric disorders. As the focus was on emerging data for the use of mental health disorders, we omitted addiction and neurological disorders, which have been extensively covered elsewhere [10, 19], cf. pain [20,21,22], cf. epilepsy [23, 24], cf. movement disorders . A further motive for this paper focusing solely on psychiatric disorders, concerns cannabis users noting that self-reported anxiety, insomnia, and depression symptoms are amongst the most common reasons for usage .
Thus, the primary purpose of this paper is to provide a systematic review of the current state of evidence in the emerging field of cannabinoid therapies for psychiatric disorders (PTSD, generalised anxiety disorder, social anxiety, insomnia, psychotic disorders, and attention-deficit hyperactivity disorder: ADHD). In addition, this review provides clinical prescriptive guidelines and consideration of both safety and occupational public health issues. We also provide discussion on considerations for future research in the field. Our intention was to provide a review of the extant literature to inform a discussion with clinical context and appropriate recommendations.
Due to the field still being in its infancy, a broad inclusion criteria was applied to the available data. The purpose was to locate human studies involving whole cannabis plant medicines and cannabis-derived isolates (singularly or in combinations) for the treatment of major psychiatric disorders or mental health symptoms. Synthetic cannabinoid analogues (e.g. nabilone) and THC isomers (e.g. dronabinol) were omitted as these fall under the auspices of a pharmaceutical-focused review (as these are classified as pharmaceutical ‘drugs’).
Major electronic databases including OVID MEDLINE, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, Allied and Complementary Medicine and PsychINFO were accessed for data up to July 2019. Initially, data were sought for meta-analytic or systematic review level epidemiological evidence (as there is sufficient data available) on the cross-sectional or longitudinal association of cannabis use and individual psychiatric disorders or symptoms. This was undertaken to assess any deleterious relationship between cannabis and psychiatric disorders. We then specifically sought any literature involving interventional human trials and observational studies, including case studies (due to deficient randomised controlled trials [RCTs] in this emerging area). We included studies with any sample size or age or gender, which used either inhalant, oral, or transdermal administration of medicinal cannabis or cannabis-derived isolates. All studies in English were assessed for inclusion (see supplementary data for the PRISMA flow chart for the number of human clinical trials or case studies excluded/included). The results are presented to firstly cover the major current epidemiological evidence, and then next all available clinical trial or case study data.
The following search terms were used to locate human studies or case report publications:
TITLE: cannab* OR THC OR tetrahydrocannabinol OR canab*
TITLE: depression or depressive or mental illness* or mental disorder* or mental health or mood disorder* or affective disorder* or anxi* or panic disorder or obsessive compulsive or adhd or attention deficit or phobi* or bipolar or psychiat* or psychological or psychosis or psychotic or schizophr* severe mental* or serious mental* or antidepress* or antipsychotic* or post traumatic* or personality disorder* or stress
In summation, 481 articles were located, which was reduced to 310 after duplicates were removed. Of these, 13 studies fitted the eligibility criteria as clinical studies of cannabis-based treatments for symptoms of psychiatric disorders. The full search and screening process is displayed in the supplementary data. There were insufficient homogenous studies to perform a meta-analysis.
The endocannabinoid system has been found to be a modulator of anxiety and mood, with recent data showing that cannabinoids or substances which target this system may interact with specific brain regions, including the medial prefrontal cortex, amygdaloid complex, bed nucleus of stria terminalis, and hippocampus . Interaction with the CB1 receptor has a modulating effect on GABAergic and Glutamatergic transmission , while also influencing the hypothalamic pituitary adrenal (HPA) axis, immune system activation, and neuroplastic mechanisms. In respect to specific psychotropic mechanisms of action, the anxiolytic (and antidepressant effects) may also in part be mediated via CBD’s serotonergic effects via 5-HT1A receptor activation , and THC’s CB1 receptor agonism [30, 31]. It is worth noting that studies have demonstrated that CBD may partially inhibit the psychoactive effects of THC, with CBD and THC having demonstrated differing symptomatic and behavioural effects on regional brain function [32,33,34,35].
As in the case of certain other psychiatric symptoms and disorders, epidemiological evidence indicates that there is a relationship between cannabis use and anxiety symptom levels. This association (assessed by Kelzior and colleagues  via meta-analysis of 31 studies) has to date only been found to be weak, and based largely on cross-sectional data. Thus, it may be that those with anxiety seek cannabis treatment, rather than a causal effect occurring from cannabis use. Longitudinal data is also not convincing due to the bias of one study with a large odds ratio included in their meta-analysis. However, a stronger positive association was revealed between anxiety and cannabis use disorder. Other longitudinal data involving the USA-based National Epidemiologic survey on Alcohol and Related Conditions  confirms there is no obvious causal inference. The study included individuals with a diagnosis of any anxiety disorder during the initial 4-year data collection period, comparing cannabis nonusers to users, and also individuals with cannabis use disorder at a later time point on a range of psychosocial measures. Results revealed that, when controlling for baseline confounders, no significant relationship was found with cannabis use and a greater frequency of anxiety.
While to date no human trials could be located for treatment of Generalised Anxiety Disorder using whole cannabis plant extracts or combined isolates, there was one study identified testing CBD (Table 1) for Social Anxiety Disorder. One small preliminary double-blind RCT compared the effects of a simulated public speaking test on treatment-naïve patients with social anxiety (n = 24) versus healthy control participants (n = 12) . Each group received a single acute oral dose of CBD (600 mg) 1.5 h before the test, or matching placebo. Results revealed that pre-treatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in the social anxiety group’s speech performance, and significantly decreased hyper-alertness in their anticipatory speech compared to the placebo group (which presented higher anxiety, cognitive impairment, discomfort, and higher alertness levels). Neuroimaging research has also revealed that in individuals diagnosed with social anxiety, cerebral blood flow may be altered via CBD. One study employed fMRI in 10 treatment-naïve patients with social anxiety who were given 400 mg of oral CBD or placebo in a double-blinded crossover manner. Relative to placebo, 400 mg of CBD was associated with significantly decreased subjective anxiety, with blood flow being modulated in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus, and the right posterior cingulate gyrus . This suggests that CBD’s activity may occur via interaction with the limbic and paralimbic brain areas.
Due to the small sample sizes, the above data needs to be considered with caution. Further, appropriate and considered treatment of anxiety disorders with cannabinoid therapies is crucial due to the complex relationship with substance use disorders, often requiring a more complex biopsychosocial approach . With this context in mind, CBD (being a non-intoxicant compared to THC) may be a more preferable option, having also shown anxiolytic effects in preclinical studies .
In respect to planned or ongoing research, one study in Colorado USA has just commenced and is exploring the anxiolytic effects of vaporised or ingested THC/CBD in differing ratios (1:0, 1:1, 0:1) in people with mild-moderate anxiety . Another study is assessing the effect of CBD on reducing symptoms of anxiety disorders in a youth cohort (12–25 years old). The Australian-based study is a 12-week open-label pilot, which aims to see if 200 mg–800 mg of oral CBD (titrated depending on age, tolerability, and efficacy) is safe and effective for a youth population .
Post-traumatic stress disorder (PTSD)
Whole plant cannabis use for the management of PTSD symptoms has been identified in usage analyses , and in particular in returned armed services veterans . The proposed neurobiological mechanisms by which medicinal cannabis may assist with PTSD are varied and mostly derived from animal research. There are high concentrations of endocannabinoid receptors in the prefrontal cortex, amygdala and hippocampus , having a role in fear acquisition and extinction . There is strong evidence revealing that a disruption of the endocannabinoid system impairs fear extinction in CB1 knockout mice, suggestive of a critical role of CB1 receptors (and thereby potentially THC) being related to the extinction of fear [48,49,50].
One survey involving a convenience sample of 170 patients via a medical cannabis dispensary in California evaluated a range of health elements, the frequency of cannabis use, and general mental health . Results revealed that those with high PTSD scores (assessed via The PTSD Checklist-Civilian Version) were more likely to use cannabis to assist with mental health coping, in addition to improving sleep, when compared with those with low PTSD scores. In particular, cannabis use frequency was greater among those with high PTSD scores who often used this for improving sleep. While there is increased use of cannabis in those with PTSD, there is currently no firmly supportive epidemiological data. A cross-sectional case control study of veterans showed that regular users do not have lower PTSD symptoms than non-users .
A recent open label retrospective analysis of case study data from 11 adults with PTSD assessed the patients over 8 weeks of CBD treatment (capsule or spray; mean dosage at week-8 of 49 mg) . Results revealed that a reduction in mean PTSD symptoms occurred in 28% of the sample, as assessed on the PTSD checklist for DSM-5 (PCL-5). Statistical data analysis was not conducted, however, and thereby it is not possible to draw firm conclusions. Another retrospective study analysing PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program during 2009 to 2011 , revealed more supportive findings. The data identified a greater than 75% reduction in Clinician Administered Posttraumatic Scale for DSM-IV (CAPS) symptom scores when patients with PTSD were using cannabis compared to when they were not. While this study had a small sample, and is a retrospective analysis that has some methodological weaknesses, a 75% reduction on the CAPS is a compelling result, and has spurred recent RCTs which are currently in recruitment [55, 56].
Phytocannabinoids and terpenes have a potential application for modulation of the endocannabinoid system and the 5HT1A receptor to provide an antidepressant effect . No RCTs to date have been conducted on the primary outcome of depression. Three studies assessing oral-administered nabiximols (i.e. botanically derived preparation containing standardised levels of THC, CBD, terpenes and flavonoids from cannabis) for other conditions (multiple sclerosis and cannabis withdrawal) found no significant effect on the secondary outcome of depression [57,58,59]. It is worth noting that one study involving cancer patients using nabiximols showed a significant reduction in mood occurred for those who used the highest dose (11–16 sprays per day) compared to the placebo . Further, some epidemiological evidence has revealed a greater level of depressive symptoms in heavy cannabis users compared to light-users and non-users . Due to this, higher dose THC should be avoided in people with major depressive disorder (MDD) or low mood. However, a cross-sectional survey on patterns of use and perceived efficacy suggested that in over 1429 participants identified as medical cannabis users, over 50% reported using medicinal cannabis specifically for depression .
Anecdotal survey evidence abounds for the soporific effect of cannabis, with sufferers of a range of conditions including pain, anxiety and PTSD reporting that it assists in the management of insomnia [51, 63,64,65,66,67,68]. While this may commonly take the form of whole plant cannabis being administered via vaporised inhalation, isolated CBD may also be of benefit. An example case study detailed in the literature concerns a 10-year-old girl with prior early childhood trauma . A trial of oral CBD oil (25 mg) resulted in a decrease in this patient’s anxiety, and improvement in the quality and quantity of her sleep. A more substantial retrospective case series of 72 adults given CBD for anxiety and sleep complaints at a psychiatric clinic (as an adjunct to usual treatment) assessed patient data monthly over 12 weeks . Anxiety scores on the Hamilton Anxiety rating Scale (HAMA) decreased within the first month in 79% of the sample and remained low during the study duration. The Pittsburgh Sleep Quality Index score also improved within the first month in 67% of the sample, but fluctuated over time. It should be noted that the data were not analysed for statistical significance, and it appeared that the sub-sample presenting primarily for anxiety treatment did not fare as well as the cohort presenting primarily with sleep issues.
A study by Johnson et al.  tested the long-term safety and tolerability of a THC/CBD spray and a THC spray in relieving pain in patients with advanced cancer. A total of 43 patients were continued on a previous three-arm RCT involving an open label administration of a self-titrated THC/CBD spray (n = 39) or THC spray (n = 4) (2.7 mg) assessed over a 5-week period. While results revealed a consistent reduction in perceived pain, participants also reported a decrease in their insomnia, which also reflected less fatigue. Cannabinoids may have a dual effect of lessening pain (which makes it easier to sleep), in addition to their direct soporific and anxiolytic effects being mediated in part via serotonergic activity.
As detailed above, the evidence for this use is currently very weak, and to date no RCTs were located in the literature specifically assessing cannabinoid isolates or whole plant formulas. As of late 2018, there is however, a clinical trial taking place in Australia assessing cannabinoid treatment in chronic insomnia . The study, based in Western Australia, is aiming to enrol 24 participants aged (25–70 years) who have insomnia (defined as difficulty initiating or maintaining sleep for 3 or more nights per week for at least 3 months). The intervention involves an oral MC extract (ZTL-101) or placebo given in a cross-over manner for a study period of approximately 2 months. Participants will be assessed via the clinically-validated insomnia scales, an actigraph watch, and will be assessed in a sleep centre after 2-weeks.
Consistent evidence has shown that there is a relationship between schizophrenia and cannabis use [73,74,75]. Heavy cannabis use may proceed to a diagnosis of the disorder, however, increased use may also result from ‘self-medication’. Cannabis use is cross-sectionally associated with more severe symptoms of psychosis in young people who do not meet the threshold for schizophrenia, and appears to be one high-risk component for the tumescence of the disorder . More importantly, there is also longitudinal data to support a causal relationship [77,78,79]. A 2016 meta-analysis showed that while general lifetime use is not cross-sectionally associated with increased risk of psychosis, there is a robust relationship demonstrated in recent or current use in ultra-high-risk (UHR) adolescents with a DSM-diagnosed cannabis use disorder . A recent prominent study has corroborated this finding. Data from 11 sites across Europe and Brazil involving patients with first-episode psychosis versus population controls, revealed that daily cannabis use was associated with increased odds of a psychotic disorder occurring compared with never-users, with nearly five-times increased odds for daily use of high-potency THC types of cannabis . Several academics [82,83,84,85,86] have disputed these findings and comment that while there is a relationship, cannabis use is not causally related to increased psychosis risk (potentially due to a range of confounders e.g. correlated genetic liabilities or indirect and bidirectional processes). However, di Forti and colleagues (the study authors)  maintain that the data does indeed support this causal association, and that other research has flawed elements (e.g. previous Mendelian Randomisation studies using imprecise measurements of cannabis use).
It is of note that schizophrenia risk alleles are linked to cannabis use in a general population . Regardless, the transition rates from a general population of cannabis users to schizophrenia is very low and can be considered to be part of a constellation of various potential gene-environment interactions. Several key genes have been implicated as potentially modulating the risk of developing schizophrenia after early cannabis use: BDNF, CNR1, COMT, AKT1, and DRD2 genes [88, 89]. There is also a likely increased susceptibility when a combination of these at-risk alleles from these single nucleotide polymorphisms (SNPs) are combined with childhood trauma [90, 91].
The apprehension regarding the promotion of psychotic symptoms are primarily based on the THC constituent of cannabis, a CB1 receptor agonist, which is the primary psychoactive phytochemical. This effect has been shown to be more prominent in users of high-THC cannabis, or in chronic heavy users . Thus, THC should be avoided in people with or at risk of schizophrenia. Exposure to THC increases extracellular dopamine and glutamate and decreases GABA concentrations in the prefrontal cortex . A recent double-blind crossover RCT investigated whether altered striatal glutamate (measured via proton magnetic resonance spectroscopy) was a mediating biomarker from intravenously administered THC in 16 healthy participants . Results revealed that that an increase in striatal glutamate levels may underlie acute cannabis-induced psychosis, while lower baseline levels may provide a valid biomarker of greater sensitivity to its acute psychotomimetic effects.
The psychotropic effects of THC may mimic the presentation of psychotic symptoms, including paranoia, sensory alteration, euphoria, and hallucinations . In laboratory-based research, people with schizophrenia appear to be even more sensitive to the psychosis-inducing effects of THC than healthy controls . In contrast to THC, as mentioned in the introduction, CBD may in fact provide an opposing effect to THC albeit more research into this mechanism is required. Additional effects include the inhibition of anandamide breakdown via fatty acid amide hydrolase (FAAH) blocking effects, and anti-inflammatory effects [97, 98].
CBD is well-tolerated with minimal deleterious psychoactive effects (although some psychological effects are evident due to modulation of the 5HT1A receptor and enhanced anandamide signalling) . Due to this, studies have primarily employed isolated CBD, however this work could potentially be extended to formulas from whole-plant strains which are high in CBD (> 10 mg/g) and lower in THC (< 4 mg/g). These preparations may also contain other yet-to-be-studied compounds from the plant which may be beneficial for the positive or negative symptoms of schizophrenia.
In respect to current research, aside from an initial index case study conducted by Zuardi, Morais  in 1995, who showed that 1500 mg of CBD administered for 26 days was beneficial for treatment-resistant schizophrenia, three clinical studies exist to date. A study by Leweke, Piomelli  tested in a double-blind, RCT design 600–800 mg/day of oral CBD vs the antipsychotic amisulpride over 4 weeks in 42 patients. While both treatments were safe and led to significant non-differential clinical improvements, the CBD arm had a superior side-effect profile. CBD also significantly increased anandamide levels, which was associated with clinical improvement. Another double-blind parallel-group trial, involving 88 patients with schizophrenia who were given either oral CBD (1000 mg/day) or placebo adjunctively to existing antipsychotic medication revealed after 6 weeks of treatment that the CBD group had lower levels of positive psychotic symptoms on the Positive and Negative Syndrome Scale (PANSS), and were more likely to have been rated as improved via clinician-ratings . While these studies were supportive of CBD, a recent double-blind RCT by Boggs, Surti  found no benefit for 600 mg/day of CBD in comparison to placebo. The 6-week study involving 36 patients with schizophrenia revealed that both placebo and CBD PANSS scores improved, but no Group × Time effect was evident. The CBD was well-tolerated, however, and more sedation was evident in the CBD group compared to placebo.
Furthermore, CBD may confer some protective effects in young people at clinical high-risk for psychosis (n = 33), as a recent single-dose RCT found that 600 mg of CBD temporarily normalised aberrant brain activity in the parahippocampal, striatal, and midbrain areas, which is associated with increased psychosis risk . Currently, an ongoing clinical trial in the United Kingdom is assessing the efficacy of 600 mg of CBD per day for reducing symptoms of psychosis in young people at clinical high-risk for psychosis .
To date no clinical trial has assessed cannabinoids for the treatment of bipolar disorder (in respect to maintaining euthymia, or as a treatment of hypo/mania or depression), although there is a potential role of the endocannabinoid system in the disorder, as detailed above. Initial case reports contend this approach may not however be of benefit . Two patients diagnosed with DSM-IV Bipolar type I disorder, and presenting with mania, were provided adjunctive CBD (titrated to 1200 mg per day) after receiving placebo for an initial five-day period. On Day 31, CBD treatment was discontinued and replaced by placebo for five days. While the first patient showed symptom improvement while on olanzapine plus CBD, she showed no additional improvement during CBD monotherapy, while the second patient had no symptom improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported, despite no obvious effect on reducing mania.
Evidence has revealed that adults with ADHD may self-medicate with cannabis as a coping strategy for a range of potential effects . Off-label use in the US for this application has been noted despite a relative deficit of evidence for this use . One study was located, the “Experimental Medicine in ADHD-Cannabinoids” pilot RCT, using nabiximol (cannabinoid/terpene combination) oromucosal spray in 30 adults with ADHD for 6 weeks . The primary outcome was cognitive performance and activity level (as measured by head movements) using the Quantitative Behavioural Test. Secondary outcomes included ADHD and emotional lability symptoms. While a trend towards significance occurred in favour of nabiximols, no significant difference was revealed on the primary outcomes. Notably, the use of nabiximols did not impair cognition. For secondary outcomes, the combination of note was associated with a nominally significant improvement in hyperactivity/impulsivity scores on the investigator-rated Conners Adult ADHD Rating Scale. The combination was well-tolerated, however, a serious adverse event involving muscular seizures/spasms occurred in the active group. While not definitive, this study provides preliminary evidence supporting the self-medication theory of cannabis use in ADHD and the need for further studies of the endocannabinoid system in ADHD. Results, however, did not meet significance following adjustment for multiple testing, and it should be recognised that the sample size was small, thus a more robust sample would be better placed to determine the true effect.
As the present data indicates, the current field of cannabinoid therapeutics in psychiatry currently provides no convincing evidentiary support for use in any mental health application. More research is urgently needed, and many RCTs are currently being undertaken; thereby the landscape will change rapidly over the next several years. Currently, the most promising (although inconclusive) evidence is for CBD as an adjunctive treatment in schizophrenia, with an additional isolated study showing efficacy in social anxiety, and weak data suggesting a potential effect for ADHD symptoms. The evidence also tentatively suggests that a role exists for cannabinoids in PTSD, and also in reducing insomnia, which may also commonly occur in chronic pain. For other plant-derived cannabinoid therapy applications for psychiatric symptoms/disorders (e.g. several affective disorders) no firm conclusions can currently be drawn.
Clinical prescriptive considerations
It initially should be recognised by clinicians that, as detailed above, weak evidence currently exists in the field, thus this prescriptive advice should be taken in the context of evolving research. The first consideration faced by a clinician (in a legal jurisdiction) with a patient who is interested (or for clinician-initiated prescription) in using cannabis medicinally, is whether this is medically appropriate for them. A thorough screening firstly needs to occur, with Canadian British Columbian Physician guidelines  suggesting that clinicians initially assess:
Age – higher-dose THC forms not advised in people < 25 years of age;
If a personal history or family history of psychosis is present, and if so, no THC is advised;
Any current or past drug or alcohol misuse or dependence (avoid especially in individuals with cannabis dependence or misuse);
Cardiovascular or respiratory diseases (avoid or use caution);
Current medications which may interact with cannabis; and
Pregnant or planning or conceive or breastfeeding (avoid).
Next, if no contraindication is apparent, medical consideration can be given to what potential clinical application the MC may present for, and the cannabis formulation or isolate/s that may be appropriate for them. Given the complexity of MC whole-plant formulas (and the current challenge to standardise for batch-to-batch consistency), companies have primarily tested cannabinoid isolates and analogues. The most studied including nabiximols (Sativex), nabilone (Cesamet), and dronabinol (Marinol). While this may provide more pharmacological assurity, such an approach also negates the potential of unique genetic chemovars of cannabis which may provide specific therapeutic activity due to a complex synergistic interaction of constituents (known as the entourage effect). Patient preference may also be towards vaporisation of dried raw material . To this end, specific prescriptive considerations need to be adopted, including:
Determining patient preference regarding administration – vaporisation (via specific devices), inhalation via traditional smoking apparatuses, oral dose (i.e. capsule, oil or in some cases food product), sublingual via lozenges or sprays. Note that each has a different onset of action and half-life. Inhalants will provide a more instantaneous effect (due to the alacrity of THC decarboxylation), whereas oral forms will take longer e.g. 45–90 min to take effect. Both forms of administration may be advisable to provide flexible symptom management;
Patient’s personality in terms of the effects of higher THC formulas. Avoidance of higher THC formulas should occur in youth and in those with paranoid personalities;
Potential for abuse (with greater theoretical potential in vaporised/inhaled forms [which also carries additional general health consequences]);
When the application should occur with respect to occupational and carer responsibilities and driving. Note that there is the potential to prescribe different cannabis preparations which contain differing levels of THC and CBD, with higher dose THC applications being applied preferentially in the evening.
CBD dosage (based on current evidence) varies according to disorder, age, weight, and potentially pharmacogenetic differences. Most research tends to focus on a range of 200 mg–800 mg per day . In respect to THC-containing formulas, it has been advised to be cautious exceeding 20 mg per day due to potential side effects , and people may find a psychotropic effect with as little as 1 mg–2.5 mg per dose.
As mentioned above, there are a myriad of potential cannabis chemovars that can be developed, each with unique medicinal applications. However, to maintain pharmacodynamic/kinetic consistency, at present, the two major constituents commonly standardised for are THC and CBD (in some cases select terpenes are also included). THC provides, as indicated above, the primary psychotropic effect, and higher doses may be preferable for the amelioration of pain and inducement of sleep . Further, it may provide an acute mood elevating effect in some people, however as mentioned, this may also elicit symptoms of paranoia, anxiety, and cognitive impairment (and in higher doses may actually impair mood). This effect may potentially be opposed by CBD (and/or other less studied cannabinoids), however data is mixed as to this effect. Additionally, the findings are not clear cut, with users of cannabis (to treat anxiety) having a statistically significant preference for higher THC/lower CBD containing cannabis cultivars .
Clinicians needs to be aware that cannabinoid therapies may elicit a range of side effects. In respect to potentially expected side-effects from cannabinoid interventions, occasional adverse effects revealed in clinical trials include co-ordination problems, dizziness, disorientation, euphoria, drowsiness or fatigue, dry mouth, nausea and gastrointestinal upsets . Due to this, regular monitoring is advised, especially when commencing treatment in cannabis-naïve patients.
The previously cited report conducted by the National Academy of Sciences  on the health effects of cannabis and cannabinoids cites limited evidence that cannabis use increases the rates of initiation of other psychoactive drugs. Additionally, while there are concerns over the relationship with schizophrenia, no firm evidence shows any association between cannabis use and the likelihood of developing bipolar disorder. Further evidence is suggestive that smoking cannabis on a regular basis is associated with cough and phlegm production, while limited evidence exists suggestive of a statistical association between cannabis use and ischaemic stroke and/or acute myocardial infarction. Evidence is noted to exist for the association between increased cannabis use frequency and progression to developing problematic cannabis use , as well as potential respiratory infections/disorders (especially in the use of poor-quality raw material). Clinicians need to balance these concerns together with the potential benefits, especially regarding the potential for lesser harm from other prescriptive or illicit options in patients managing psychiatric and pain conditions.
Increased attention to the influence of pharmacogenetics factors is advised, with several genes being identified that may differentially affect cannabinoid pharmacokinetics and pharmacodynamics. A recent review led by Hryhorowicz  characterised pertinent genes with relevant interaction with cannabis into three broad categories: Receptor genes (CNR1, CNR2, TRPV1, and GPR55), transporter genes (ABCB1, ABCG2, SLC6A) and pharmacokinetic/metabolism (CYP3A4, CYP2C19, CYP2C9, CYP2A6, CYP1A1, COMT, FAAH, COX2, ABHD6, ABHD12). Research into the pharmacogenomic influence is however nascent, with most of the focus being on the relationship with cannabis dependence (e.g. CNR1 receptor SNPs which shows no obvious association), or schizophrenia (COMT, DRD2 SNPs showing a stronger correlation) [81, 114]. Further exploration of FAAH SNPs differentially affecting people’s response to CBD is also of value (given its important role in inhibiting the degradation of anandamide).
Occupational and public health considerations
Occupational health and safety issues also exist in consideration with medicinal cannabis users. Workplace safety concerns have been raised in relation to the potential for medicinal cannabis use to impair judgement and psychomotor skills, especially in relation to motor vehicle use, operation of fixed and mobile plants particularly heavy industrial machinery, and the potential for risk-taking behaviors and those working in safety sensitive positions [115, 116]. Employers have a ‘duty of care’ to provide safe and healthy workplaces, which includes the management of alcohol and drug use and their potential to create unsafe workplaces or practices. Workplace drug testing (WDT) is common in some industries including mining, transportation and correctional services . Employees in building, transportation, maritime and mining operations cannot use drugs, legal or illegal, if they could impair their ability to safely undertake their duties . However, the presence of a drug, or its metabolite, in a person’s system is not always proportional to cognitive impairment . In addition, WDT does not discriminate between recreational or medicinal use and could place medicinal cannabis patients at risk of discrimination or unfair dismissal. Implementation of WDT should be balanced with a greater knowledge on the dose response relationship between cannabis-based medicines and their potential side effects.
Medicinal cannabis patients may also be subject to mobile drug testing in jurisdictions such as Australia. The salivary testing process is inefficient for assessment of cannabis related driving impairment because the tests can trace THC in saliva for days after consumption, long after any cognitive impairment has abated. The potential impact of medicinal cannabis on function will vary with dose, the length of usage (tolerance), route of administration (oral versus smoking),  and saliva THC levels are not direct measures of cognitive status. Further, the concentration of THC in urine does not correlate with cognitive function . Conversely, in the US, a whole blood THC level of 5 ng/mL has been established as a legal limit for driving in states where cannabis has been legalised . Guidelines and strategies for the specific risk management of cannabis in the workplace have been published in North America [120,121,122,123]. However, Australia is yet to publish its own risk management guidelines relating to medicinal cannabis in the workplace, although generic workplace alcohol and drug risk management guidelines could be adapted in the interim .
Future research considerations
It should also be noted that the majority of studies assessing the effect of cannabis on cognitive function were undertaken with low potency THC strains (< 4% THC),  and further study is required for both high potency THC medicines, as well as THC-free medicines such as CBD . Further, more research is needed on the dosage required (especially of CBD and lesser studied cannabinoids), the potential entourage effect, the pharmacokinetics, and the influence of pharmacogenetics on both metabolism of the cannabinoids and the pharmacodynamics. Novel trial designs are advised in some instances, particularly involving employing high-quality RCTs (or N-of-1 designs), to explore the potential benefits in psychiatric conditions.
While research is rapidly advancing, there is a challenge regarding the adequate blinding of medicinal cannabis studies (due to the obvious psychotropic effect, and lack thereof in cannabinoid-removed controls) . This may be addressed via cannabis naïve participants with psychomimetic controls (e.g. atropine; these however have the innate challenges of being biologically active themselves); adequate assessment of un/blinding; and use of varying levels of THC within the study. It still should, however, be taken in the context of other psychiatric or neurological research, with opioids and benzodiazepines also eliciting an obvious psychophysiological effect, and the acceptance of the research demonstrating analgesic and anxiolytic effects, respectively.
Currently the evidence is nascent and too weak to recommend cannabinoid-based interventions for a range of psychiatric disorders. While encouraging, research is only just beginning to determine whether cannabis or its isolates may or may not be effective for this application, and clinicians need to be mindful of several safety considerations (as articulated above). The most promising (although inconclusive) evidence is for CBD as an adjunctive treatment in schizophrenia, with an additional isolated study showing efficacy in social anxiety, and some data suggesting a potential effect for PTSD and ADHD symptoms. The data also tentatively suggests that a role exists for cannabinoids in reducing insomnia, which may also commonly occur in chronic pain. Given the generally favorable safety profile of cannabinoids observed across the observational studies and clinical trials conducted to date, there is clearly a strong case for encouraging further research.